Dr. Reddy's Laboratories Limited
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisi...
Latest News
6 days ago · zacks.com
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallDr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
8 days ago · fool.com
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term InvestorsSemaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.
10 days ago · seekingalpha.com
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call TranscriptDr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
10 days ago · marketbeat.com
Dr. Reddy's Laboratories Q2 Earnings Call HighlightsDr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.
2 months ago · reuters.com
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in IndiaDr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
3 months ago · businesswire.com
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United StatesHYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States.
3 months ago · youtube.com
U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEOIn this CNBC exclusive, Dr. Reddy's Laboratories CEO Erez Israeli breaks down the company's recent Q1 earnings report. He addresses the temporary halt in Semaglutide production due to an impurity issue and weighs in on Trump administration's vow to increase generic drug import tariffs to 100% by 2030.
3 months ago · cnbc.com
U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warnsU.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing of generic drugs in India leads to a significant decrease in the cost of medicine to the United States.
3 months ago · gurufocus.com
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells InvestorsOn July 23, 2026, Dr Reddy's Laboratories Ltd (RDY) shares rose 3.7%, bringing the current price to $11.80. The stock has experienced notable volatility, with a
3 months ago · zacks.com
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock DownRDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RDY